Bicara Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted strong clinical activity and durability for a bifunctional EGFR TGF-beta antibody in HPV-negative head and neck cancer, with a 21% complete response rate and robust safety profile. A pivotal phase III trial is underway, and commercial infrastructure is being built for a U.S. launch.
-
FICERA, a bifunctional antibody targeting EGFR and TGF-beta, is showing strong efficacy and durability in HPV-negative head and neck cancer, with a pivotal trial progressing globally and FDA support for the 1,500 mg dose. Commercial launch is planned for 2028, with expansion into CRC and PDAC underway.
-
Ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows high response rates, deep and durable responses, and a favorable safety profile at both weekly and less frequent dosing. Biomarker and clinical data support a move to a loading/maintenance regimen, with regulatory plans for flexible dosing.
-
Significant clinical progress was made with ficerafusp alfa, including FDA breakthrough designation and strong survival data in HPV-negative head and neck cancer. The pivotal phase III study is underway, with commercial launch targeted for early 2028 and expansion into other solid tumors planned.
Fiscal Year 2025
-
Achieved key milestones with FDA breakthrough therapy designation and strong clinical data for ficerafusp alfa, advancing to phase III and securing $161.8M in new funding. Cash runway extends into 2029, supporting regulatory, commercial, and development initiatives.
-
Ficerafusp alfa plus pembrolizumab shows high response rates and manageable safety in HPV-negative HNSCC, with deeper and more durable responses at the 1,500 mg dose. Dose selection for the pivotal FORTIFY-HN01 trial is expected in Q1 2026, with data supporting the higher dose.
-
Ficerafusp alfa has shown significant improvements in response and survival for head and neck cancer, with both 750 mg and 1,500 mg doses under evaluation. The pivotal trial uses a seamless design for potential accelerated approval, and less frequent dosing is being explored to enhance patient convenience.
-
Ficerafusp alfa, a bifunctional EGFR-TGF-β1/3 inhibitor, is showing strong efficacy in HPV-negative head and neck cancer, with pivotal trials on track and a robust regulatory and commercial strategy. The program is well-funded, expanding into additional indications, and leveraging AI for development.
-
Lead EGFR TGF-beta bifunctional shows strong survival benefit in head and neck cancer, with pivotal trials underway and expansion into colorectal and locally advanced settings planned. Dose optimization and companion diagnostics are advancing, with robust funding supporting operations through 2029.
-
Ficerafusp alfa, a bispecific EGFR/TGF-beta inhibitor, is showing promising efficacy and durability in HPV-negative head and neck cancer, with pivotal trial milestones and dose selection expected in the next year. The program is well-funded and aims to set a new standard of care.
-
Bicara presented strong clinical data for ficera, a bifunctional EGFR-TGF beta inhibitor, showing over 21 months median overall survival and deep, durable responses in HPV negative head and neck cancer. Ongoing phase II/III trials are designed for accelerated approval, with robust patient selection and biomarker-driven strategy.
-
Ficerafusp alfa plus pembrolizumab shows deep, durable responses and improved survival in HPV-negative head and neck cancer, with a 54% response rate and 21.3-month median OS. The pivotal FORTIFI-HN01 trial is enrolling globally, targeting accelerated approval in this high-need population.
-
Ficera, a bifunctional antibody, is showing promising efficacy and durability in HPV-negative head and neck cancer, with pivotal trials underway and expansion into other tumor types. Key data updates are expected at ASCO and AACR, and the market opportunity is estimated at $3-4 billion globally.
Fiscal Year 2024
-
Ficerafusp alfa demonstrated high response and complete response rates in HPV-negative head and neck cancer, with strong durability and a favorable safety profile. The registrational trial is set to begin soon, supported by robust funding, and expansion into additional tumor types and earlier disease stages is planned.